Cyclo Therapeutics, Inc.
CYTH · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.8% | -13.2% | 75.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 90.9% | 89.9% | 90.2% | 92.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,860.9% | -1,134.1% | -899.9% | -990.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,863.4% | -1,110.7% | -902.1% | -987.7% |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 |
| % Growth | 32% | 19.6% | 59.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |